Patients with Fanconi anemia (FA) have an increased risk for head and neck squamous cell carcinoma (HNSCC). The authors sought to determine the prevalence of undiagnosed FA and FA carriers among patients with HNSCC as well as an age cutoff for FA genetic screening. METHODS: Germline DNA samples from 417 patients with HNSCC aged <50 years were screened for sequence variants by targeted next-generation sequencing of the entire length of 16 FA genes. RESULTS: The sequence revealed 194 FA gene variants in 185 patients (44%). The variant spectrum was comprised of 183 nonsynonymous point mutations, 9 indels, 1 large deletion, and 1 synonymous variant that was predicted to effect splicing. One hundred eight patients (26%) had at least 1 rare variant that was predicted to be damaging, and 57 (14%) had at least 1 rare variant that was predicted to be damaging and had been previously reported. Fifteen patients carried 2 rare variants or an X-linked variant in an FA gene. Overall, an age cutoff for FA screening was not identified among young patients with HNSCC, because there were no significant differences in mutation rates when patients were stratified by age, tumor site, ethnicity, smoking status, or human papillomavirus status. However, an increased burden, or mutation load, of FA gene variants was observed in carriers of the genes FA complementation group D2 (FANCD2), FANCE, and FANCL in the HNSCC patient cohort relative to the 1000 Genomes population. CONCLUSIONS: FA germline functional variants offer a novel area of study in HNSCC tumorigenesis. FANCE and FANCL, which are components of the core complex, are known to be responsible for the recruitment and ubiquitination, respectively, of FANCD2, a critical step in the FA DNA repair pathway. In the current cohort, the increased mutation load of FANCD2, FANCE, and FANCL variants among younger patients with HNSCC indicates the importance of the FA pathway in HNSCC. Cancer 2017;123:3943-54.
INTRODUCTION
Fanconi anemia (FA) is a rare, predominantly recessive, inherited disorder with an incidence of 1 in 130,000 births and an estimated carrier rate of 0.6%. 1, 2 Genetically, FA is a heterogeneous disease with 21 causative genes known to date, including 5 new genes that were added within the past two years. 3, 4 Phenotypically, FA is associated with congenital defects (short stature, renal defects, cafe-au-lait spots, microphthalmia, hearing difficulties, and abnormal thumb or radii) and progressive bone marrow failure. In addition to congenital anomalies and the inevitable bone marrow failure, patients with FA are at increased risk of acute myelogenous leukemia and head and neck squamous cell carcinoma (HNSCC). 5, 6 However, 30% of patients fail to display these FA congenital defects, 7, 8 and up to 25% present with solid or hematologic malignancies as the first sign of the condition. 9 In many such patients, an FA diagnosis is prompted after severe toxicities are encountered upon initiating chemotherapy or radiation therapy to treat the malignancy. 10 The pathogenesis is based on the finding that the normal function of FA genes is related to DNA repair and genome stability; biallelic mutations of these genes confer an annual risk of cancer from 0.7% to 2%, 5, 9, 11 and some, including FA complementation group D1 (FANCD1) (breast cancer 2 [BRCA2]) and FANCN (partner and localizer of BRCA2 [PALB2]), are closely associated with solid organ malignancies [12] [13] [14] HNSCC is traditionally related to tobacco and alcohol consumption and has recently been associated with human papillomavirus, and exposed individuals have a 10-fold to 15-fold increased risk of HNSCC compared with unexposed individuals. 15, 16 However, FA confers a 500-fold to 700-fold increased risk of HNSCC compared with the normal population. 9, 17, 18 The median age of HNSCC onset in patients with FA is 33 years compared with 60 years in traditional patients with HNSCC; thus, patients with FA develop HNSCC at a significantly younger age than those with sporadic HNSCC. 19 Younger patients with HNSCC have reduced DNA repair capacity, but the prevalence of FA mutations in patients with HNSCC remains unknown. 20 Because 30% of patients with FA mutations do not display the congenital stigmata of FA, we sought to determine: 1) the prevalence of undiagnosed FA among patients with HNSCC aged <50 years, 2) an age cutoff for FA screening among younger patients with HNSCC, and 3) the prevalence of FA carriers (heterozygote germline mutations) among younger patients with HNSCC.
MATERIALS AND METHODS

DNA Extraction
DNA was isolated from blood using the Puregene kit and DNeasy blood and tissue DNA extraction kit (Qiagen, Hilden, Germany) and was subjected to phenol/chloroform extraction and ethanol precipitation.
Samples for Sequencing
In total, 647 patients aged < 50 years with HNSCC were enrolled in a prospective molecular epidemiologic study of newly diagnosed HNSCC that included completion of a prospective, standardized, epidemiologic questionnaire and blood draw. Patients who had cancer (including known FA) before an HNSCC diagnosis were excluded. The Institutional Review Board of the University of Texas MD Anderson Cancer Center approved this study, and all patients provided informed consent.
Of the 617 patients initially enrolled for the study (Supporting Fig. 1 ; see online supporting information), DNA was available from 468 patients. DNA from 417 of 468 patients was of sufficient quality and quantity required for the targeted capturing and sequencing approach. Thus, DNA samples from 417 patients were sequenced. There was no difference between the sequenced group (417 patients) and the nonsequenced group (230 patients) in terms of age, sex, ethnicity, smoking, and alcohol drinking (Supporting Table 1 ; see online supporting information). There was a higher proportion of laryngeal/hypopharyngeal disease among those who were excluded and a higher proportion of oral cavity disease in those who were included.
Targeted Next-Generation Sequencing
The genomic regions representing the entire length of 16 FA genes were targeted for capturing and sequencing (Supporting Table 2 ; see online supporting information). The exceptions were the exon 1 regions of FANCA, FANCB, and FANCE, which were not covered by the sequencing approach. Excessive repeat sequences prevented the successful design of probes for exon 1 of FANCA. Probes were designed for the FANCB and FANCE exon 1 regions but did not yield product. The targeted TruSeq (Illumina Inc., San Diego, Calif) capturing design, capture, and sequencing were done as previously described. 21 
Variant Calling and Filtering
Novoalign (http://www.novocraft.com/products/novoalign/, Accessed May 24, 2017) was used for sequence alignment. The Most Probably Genotype (MPG) genotype caller (https://research.nhgri.nih.gov/software/bam2 mpg/, Accessed May 24, 2017; National Human Genome Research Institute Genome Technology Branch) was used to call variants, and SnpEff 22 was used to filter the highquality functional variants based on the following criteria: quality score 20, read depth 10, nonsense, missense, indel, and splicing (62 base pairs). The extracted functional variants were subsequently annotated and filtered using a population-specific maximum frequency, where applicable, of 0.5% in each of the 1000 Genomes (2504 individuals), the National Heart, Lung, and Blood Institute-Exon Sequencing Project 6500 (NHLBI-ESP6500) (6503 individuals), and the Exome Aggregation Consortium (ExAC) non-The Cancer Genome Atlas (60,706 individuals) variant databases. The allele frequency threshold of 0.5% is derived from the FA carrier frequency of 1:181. 2 All coordinates are in accord with Human Genome Build 19.
Predicted Damaging Variants
To predict the functional consequence of a variant, we compared the results from 5 prediction algorithms: Data from a single nucleotide polymorphism array were analyzed for copy number variations. Single nucleotide variant discovery was performed from targeted sequencing of 16 FA genes. Synonymous variants were analyzed for splicing effects. Indels and nonsynonymous and splicing variants were screened for quality and filtered using population-specific frequencies, where applicable. The resulting rare variants were screened for presence in the FA Mutation Database (FAmutDB) and ClinVar and were analyzed by functional prediction algorithms to determine potential pathogenicity (unreported variants were present at a frequency below 0.5% in the public databases but were not present in the FAmutDB, ClinVar, or Breast Cancer Information Core [BIC] databases; *novel variants were not present at any frequency in the public databases used for filtering).
edu/pph2, Accessed May 24, 2017), MutationTaster (http://www.mutationtaster.org/, Accessed May 24, 2017), Combined Annotation-Dependent Depletion (CADD) (http://cadd.gs.washington.edu, Accessed May 24, 2017), and Genomic Evolutionary Rate Profiling 2 (GERP11) (http://mendel.stanford.edu/SidowLab/ downloads/gerp/). We used a minimum threshold of 20 for Phred-scaled CADD scores, representing the 1% most damaging variants in the genome, and a minimum threshold of 2 for GERP1 1 rejected substitution scores. GERP1 1 was included to highlight constrained sites. Annovar 23 was used to annotate the variants with the results from all 5 prediction algorithms. For consideration as a "damaging" variant, at least 4 of the 5 algorithms had to meet their specified threshold. "Benign" variants did not meet the threshold in at least 4 of the 5 algorithms. Variants lacking consensus between at least 4 algorithms were labeled as "indeterminate" (Fig. 1 , Supporting Table  3 ; see online supporting information).
Previously Reported Variants
The following databases were used to identify previously 
Synonymous Variants
Synonymous variants with quality scores 20 and a read depth 10 were analyzed using SILVA v1.1.1. 24 Variants that were determined to be "potentially pathogenic" by SILVA were further analyzed using NetGene2 25 to predict splicing effects.
Single Nucleotide Polymorphism Array Analysis
The patient DNA samples were run on the Illumina HumanExome BeadChip, which contains approximately 250,000 single nucleotide polymorphisms. The data were processed using GenomeStudio (Illumina, Inc.), and copy number variants were detected using cnvPartition v3.2 (Illumina, Inc.) and Nexus v7.5 (BioDiscovery, Inc., El Segundo, Calif).
Statistical Analysis of Mutation Load
The Mann-Whitney-Wilcoxon nonparametric statistical test was used to evaluate the burden or mutation load of FA gene variants in the HNSCC patient cohort compared with the 1000 Genomes data set. Because the HNSCC cohort was comprised predominantly of patients of Caucasian ethnicity (Table 1) , the statistical test was performed using data from the 356 Caucasian patients with HNSCC and the 503 EUR 1000 Genomes individuals (of European ancestry) to create a more homogenous comparison group. We obtained the nonsynonymous and indel variant alleles from each set and implemented the test in R (R Foundation for Statistical Computing, Vienna, Austria). 26 
Low-frequency Variants
LoFreq 27 was implemented to call low-frequency variants occurring between 5% and 40% with a genotype quality >500.
RESULTS
Of the 417 patients who had DNA available for sequencing, 88 (21%) were aged < 40 years (a traditionally accepted definition of "young" for a patient with HNSCC), 108 (26%) were ages 40 to 44 years, and 221 (53%) were ages 45 to 49 years. Tumor site was the oral cavity in 149 patients (36%), the oropharynx in 230 (55%), and the larynx in 38 (9%). The cohort was comprised of 4 different ethnic populations, 356 (85%) are Caucasian, 40 (10%) are Hispanic, 14 (3%) are Asian, and 7 (2%) are African American (Table 1) .
No patient in the cohort had a known diagnosis of FA, and there were very few with any potential signs of an FA phenotype. Classic phenotypes of FA were then evaluated in the cohort. Seventeen patients (4%) had a firstdegree relative with a hematologic malignancy, 25 (6%) had short stature (<5th percentile), and 8 (2%) had macrocytic anemia and/or leukopenia. Among the patients who had received chemotherapy, there were no grade IV toxic effects.
Germline DNA targeted capturing and nextgeneration sequencing of 16 FA genes revealed 11,968 initial variants. The targeted region for capturing and sequencing included the entire gene. The postsequence coverage of high-quality sequence, particularly for the entire coding region of 56,120 base pairs, was 100% for all genes except for a total of 287 base pairs from exon 1 of FANCA, FANCB and FANCE, with an approximate depth of coverage of 240 reads at each base (Supporting Table 2 ; see online supporting information). 21 Among the initial 11,968 called variants, there were 137 synonymous variants and 358 functional variants (nonsense, missense, indel, or splicing) (Fig. 1) . By using a population-specific variant frequency threshold of 0.5% in each of the 1000 Genomes, NHLBI-ESP6500, and ExAC databases, the subset of functional variants was Original Article further reduced to 192 (183 single nucleotide variants [SNVs] and 9 indels). Functional prediction algorithms (SIFT, PolyPhen-2, MutationTaster, CADD, and GERP11) analyzed the 183 rare SNVs to identify which are likely to induce deleterious functional consequences and which are likely benign. Assignment of a definitive prediction to a particular variant depended on at least 4 of the 5 algorithms reaching a consensus. If a consensus was not met between at least 4 algorithms, then the prediction was classified as indeterminate and labeled as such. Eighty rare SNVs were predicted to be damaging, and 64 were predicted to be benign, whereas 39 were indeterminate. The 9 indels were presumed to be deleterious by the nature of the variant. Splicing prediction algorithms (SILVA and NetGene2) analyzed the 137 synonymous variants and identified 1 variant as likely pathogenic by creating a new donor site.
The 193 resulting variants (184 SNVs and 9 indels) were compared with variants that had been previously reported to the LOVD FA disease database, BIC, and/or listed in ClinVar. Eighty-five of 193 variants (44%) had been previously reported in at least 1 of the 3 databases, but only 5 of 85 were listed specifically as pathogenic, whereas the rest were listed as either benign or of uncertain significance. Variants in BRCA2(36) and PALB2(9) comprised 52% (45 of 85) of the reported variants. In addition to the 85 reported variants, our cohort carried 38 completely novel variants and 71 variants that were unreported but were present at a frequency below 0.5% in the public databases.
In addition to high-throughput sequencing of the 16 FA genes, genotype data were collected by single nucleotide polymorphism array (HumanExome BeadChip; Illumina, Inc.) for all 417 patients with HNSCC. Copy number analysis revealed an approximately 154-kb heterozygous deletion of SLX4, spanning the entire gene, in 1 patient with HNSCC. This patient also carried an SLX4 missense mutation that was predicted to be damaging (Table 2) .
We also implemented LoFreq to call low-frequency variants (between 5% and 40%) that had quality scores >500 and a minor allele frequency <0.5% in public databases. It is known that revertant mosaicism in FA may result in the loss of a variant or a variant being present to a lower extent; and, in such patients, cancer may precede the diagnosis of FA. 28 However, our search for low-frequency variants did not yield any potential candidates.
Of all 417 patients in the cohort, 185 (44%) carried at least 1 rare variant (Table 3) . These 185 patients carried 194 variations (192 rare variants, 1 large deletion, and 1 synonymous variant that was predicted to affect splicing). A rare variant was observed in 42% to 55% of patients from Caucasian, Hispanic, and African American ancestry, whereas 11 of 14 Asian patients (79%) carried a variant. Rare variants were identified in similar proportions of patients irrespective of tumor site (larynx, 42%; oral cavity, 44%; or oropharynx, 45%) or age group (<40 years, 40%; 40-44 years, 49%; or 45-49 years, 44%) (Tables 3). The proportion of patients carrying rare predicted damaging variants also was similar irrespective of tumor site (range, 25%-28%) or age group (range, 24%-28%) (Tables 4 and 5) .
Fifteen patients (4%) either had 2 rare FA variants in the same FA gene or had an X-linked variant of FA (Table 2) . Among these 15 patients, the median age was 45 years (only 2 were younger than 40 years), 10 patients (67%) had oropharyngeal primary tumors, 8 (47%) were never smokers, 2 (13%) had a first-degree relative with a hematologic malignancy, 5 (33%) had short stature (<5th percentile), and 3 (20%) had macrocytic anemia and/or leukopenia. Relative to the entire cohort, there were no differences in age, sex, smoking status, tumor site, or human papillomavirus status between patients who did or did not carry either 2 rare variants in the same FA gene or an X-linked FA variant. Of the 15 patients who carried 2 rare variants or an X-linked variant, 6 carried variants that had been previously documented either in the FA mutation database, ClinVar, or BIC. 
Original Article
Thirty-nine patients carried a rare variant in 2 or more different FA genes (Supporting Table 4 ; see online supporting information). When comparing the age at presentation between patients with and without multiple variants, there was no difference in age, sex, smoking, alcohol use, or human papillomavirus status.
The 194 germline variations were comprised of 176 missense variants, 9 indels, 6 nonsense variants (including 1 stop loss), 2 splicing variants (including 1 synonymous), and 1 large deletion (Fig. 2, Supporting Table 3 ; see online supporting information). These variants amounted to 255 occurrences throughout the HNSCC cohort (Table 6) Table 3 (see online supporting information). Table 7 presents the incidence of rare variants by FA gene among the HNSCC cohort, segregated by tumor 12  17  7  12  3  7  Totals  194  255  91  125  38  60 Abbreviations: BRCA2, breast cancer 2; BRIP1, BRCA interacting protein C-terminal helicase 1; ERCC4, excision repair 4, endonuclease catalytic subunit (Fanconi anemia complementation group Q [FANCQ]); FANCA through FANCM, Fanconi anemia complementation groups A through M; PALB2, partner and localizer of BRCA2 (FANCN); RAD51C, RAD51 paralog C (FANCO); SLX4, SLX4 structure-specific endonuclease subunit (FANCP). a Rare indicates that the variant exists at a frequency <0.5% in the 1000 Genomes; National Heart, Lung, and Blood Institute-Exon Sequencing Project 6500;
or Exome Aggregation Consortium database. Original Article site, ethnicity, and age group. There were no significant differences in mutation rates when patients were stratified by age, tumor site, ethnicity, smoking status, or human papillomavirus status. Finally, we searched for an increased burden or mutation load of FA gene variants in our cohort compared with the 1000 Genomes data set using Mann-WhitneyWilcoxon nonparametric tests. Because our cohort is comprised predominantly of patients with Caucasian ethnicity, the statistical comparison was between the 356 Caucasian patients with HNSCC and the 503 individuals of European ancestry in the 1000 Genomes data set. This comparison revealed that FANCD2, FANCE, and FANCL had a significantly increased mutation burden in our cohort (Table 8) . At the same time, the mutation burden for BRCA2, FANCG, and FANCQ was significantly reduced.
DISCUSSION
Whereas HNSCC is highly associated with FA, the prevalence of FA germline variants in younger HNSCC populations has not been explored. Although the primary purpose of this study was to define an age cutoff for genetic FA screening among patients with HNSCC, there was no correlation of younger age with FA germline variants. In a previously reported tumor genomic analysis of HNSCC in low-risk patients (nonsmokers aged < 45 years) and traditional high-risk patients (smokers aged > 45 years), age was not a marker of genome instability: rates of gene-specific mutations and copy number alterations were similar in oral tongue cancers among lowrisk patients and oral tongue cancers among traditional high-risk patients. 29 Similarly, we did not observe a difference in the prevalence of FA germline mutations between patients ages <40, 40-44, and 45-50 years or between smokers and nonsmokers.
Our patient cohort consisted of 4 different ethnicities, so it was important to use an approach that involved population-specific frequencies to ensure that low frequency variants were properly characterized. One hundred eighty-five patients in our cohort carried 194 total variations, including 183 rare nonsynonymous variants, 1 synonymous variant that was predicted to affect splicing, 9 indels, and 1 large deletion (Fig. 1) . One hundred eight patients carried at least 1 variant that was predicted to be damaging. We identified 38 novel FA germline variants, including 1 synonymous variant and a large deletion, that were not present in control populations or had not previously been documented in disease-associated databases, of which 23 (61%) were predicted to be damaging (Fig. 1 , Supporting Table 3 ; see online supporting information). There were 15 patients who carried 2 rare alleles in the same FA gene, which included 3 who were known to have anemia and/or leukopenia and 2 who presented with short stature. FA germline variants and genome instability may play a broader role in HNSCC susceptibility regardless of age or traditional risk factors.
Mutations in the FA core complex (FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL, FANCM, and the recently identified FANCT) affect ubiquitination of the FANCD2/FANCI complex, a critical step in the FA pathway that repairs DNA damage and maintains genomic stability. 5, 30 FANCL is a member of the FA core complex with E3 ligase enzymatic activity for FANCD2 monoubiquitination. 31 FANCE recruits FANCD2 to the FA core complex for ubiquitination and subsequent DNA repair. 32 It is interesting to note that FANCD2, FANCL, and FANCE homologs form a subset of the FA genes present in Ciona intestinalis, which is believed to be the closest invertebrate relative of vertebrates 33, 34 ; thus, these homologs appear to be an evolutionarily conserved part of the FA pathway. It is likely that mutations affecting FANCD2, FANCE, or FANCL modify cancer susceptibility through altered DNA repair and genomic instability. In the current study, we observed an increased burden, or mutation load, of variants in 
